rs435080

Variant summary

Our verdict is Benign. The variant received -21 ACMG points: 0P and 21B. BP4_StrongBP6_Very_StrongBP7BA1

The NM_003126.4(SPTA1):​c.126C>T​(p.Val42Val) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.995 in 1,613,794 control chromosomes in the GnomAD database, including 799,329 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).

Frequency

Genomes: 𝑓 0.97 ( 72254 hom., cov: 31)
Exomes 𝑓: 1.0 ( 727075 hom. )

Consequence

SPTA1
NM_003126.4 synonymous

Scores

2

Clinical Significance

Benign criteria provided, multiple submitters, no conflicts B:13

Conservation

PhyloP100: -0.307

Publications

18 publications found
Variant links:
Genes affected
SPTA1 (HGNC:11272): (spectrin alpha, erythrocytic 1) This gene encodes a member of a family of molecular scaffold proteins that link the plasma membrane to the actin cytoskeleton and functions in the determination of cell shape, arrangement of transmembrane proteins, and organization of organelles. The encoded protein is primarily composed of 22 spectrin repeats which are involved in dimer formation. It forms a component of the erythrocyte plasma membrane. Mutations in this gene result in a variety of hereditary red blood cell disorders, including elliptocytosis-2, pyropoikilocytosis, and spherocytosis, type 3. [provided by RefSeq, Aug 2017]
SPTA1 Gene-Disease associations (from GenCC):
  • hereditary spherocytosis type 3
    Inheritance: AR Classification: DEFINITIVE, STRONG Submitted by: Laboratory for Molecular Medicine, Labcorp Genetics (formerly Invitae), Ambry Genetics
  • elliptocytosis 2
    Inheritance: AD Classification: STRONG, MODERATE Submitted by: Labcorp Genetics (formerly Invitae), Ambry Genetics, Laboratory for Molecular Medicine
  • pyropoikilocytosis, hereditary
    Inheritance: AR Classification: STRONG, MODERATE Submitted by: Labcorp Genetics (formerly Invitae), Ambry Genetics
  • hereditary elliptocytosis
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
  • hereditary spherocytosis
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -21 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.52).
BP6
Variant 1-158685246-G-A is Benign according to our data. Variant chr1-158685246-G-A is described in ClinVar as Benign. ClinVar VariationId is 258916.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BP7
Synonymous conserved (PhyloP=-0.307 with no splicing effect.
BA1
GnomAd4 highest subpopulation (EAS) allele frequency at 95% confidence interval = 0.994 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
SPTA1NM_003126.4 linkc.126C>T p.Val42Val synonymous_variant Exon 2 of 52 ENST00000643759.2 NP_003117.2 P02549-1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
SPTA1ENST00000643759.2 linkc.126C>T p.Val42Val synonymous_variant Exon 2 of 52 NM_003126.4 ENSP00000495214.1 P02549-1

Frequencies

GnomAD3 genomes
AF:
0.974
AC:
148054
AN:
152020
Hom.:
72200
Cov.:
31
show subpopulations
Gnomad AFR
AF:
0.910
Gnomad AMI
AF:
1.00
Gnomad AMR
AF:
0.989
Gnomad ASJ
AF:
1.00
Gnomad EAS
AF:
1.00
Gnomad SAS
AF:
0.999
Gnomad FIN
AF:
1.00
Gnomad MID
AF:
0.997
Gnomad NFE
AF:
1.00
Gnomad OTH
AF:
0.977
GnomAD2 exomes
AF:
0.993
AC:
245244
AN:
246954
AF XY:
0.995
show subpopulations
Gnomad AFR exome
AF:
0.906
Gnomad AMR exome
AF:
0.995
Gnomad ASJ exome
AF:
1.00
Gnomad EAS exome
AF:
1.00
Gnomad FIN exome
AF:
1.00
Gnomad NFE exome
AF:
1.00
Gnomad OTH exome
AF:
0.997
GnomAD4 exome
AF:
0.997
AC:
1457747
AN:
1461656
Hom.:
727075
Cov.:
71
AF XY:
0.998
AC XY:
725429
AN XY:
727134
show subpopulations
African (AFR)
AF:
0.910
AC:
30439
AN:
33460
American (AMR)
AF:
0.994
AC:
44424
AN:
44702
Ashkenazi Jewish (ASJ)
AF:
1.00
AC:
26128
AN:
26128
East Asian (EAS)
AF:
1.00
AC:
39694
AN:
39694
South Asian (SAS)
AF:
1.00
AC:
86222
AN:
86254
European-Finnish (FIN)
AF:
1.00
AC:
53414
AN:
53414
Middle Eastern (MID)
AF:
0.990
AC:
5711
AN:
5766
European-Non Finnish (NFE)
AF:
1.00
AC:
1111722
AN:
1111856
Other (OTH)
AF:
0.994
AC:
59993
AN:
60382
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.474
Heterozygous variant carriers
0
230
460
691
921
1151
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
21668
43336
65004
86672
108340
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.974
AC:
148165
AN:
152138
Hom.:
72254
Cov.:
31
AF XY:
0.975
AC XY:
72545
AN XY:
74390
show subpopulations
African (AFR)
AF:
0.910
AC:
37746
AN:
41480
American (AMR)
AF:
0.989
AC:
15091
AN:
15264
Ashkenazi Jewish (ASJ)
AF:
1.00
AC:
3472
AN:
3472
East Asian (EAS)
AF:
1.00
AC:
5160
AN:
5160
South Asian (SAS)
AF:
0.999
AC:
4819
AN:
4824
European-Finnish (FIN)
AF:
1.00
AC:
10622
AN:
10622
Middle Eastern (MID)
AF:
0.993
AC:
292
AN:
294
European-Non Finnish (NFE)
AF:
1.00
AC:
67987
AN:
67998
Other (OTH)
AF:
0.977
AC:
2064
AN:
2112
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.507
Heterozygous variant carriers
0
193
387
580
774
967
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
912
1824
2736
3648
4560
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.987
Hom.:
55067
Bravo
AF:
0.970
Asia WGS
AF:
0.995
AC:
3459
AN:
3476
EpiCase
AF:
1.00
EpiControl
AF:
1.00

ClinVar

Significance: Benign
Submissions summary: Benign:13
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not provided Benign:4
Nov 29, 2024
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

-
Breakthrough Genomics, Breakthrough Genomics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:not provided

- -

Jun 27, 2018
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Feb 03, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

not specified Benign:3
-
Genome Diagnostics Laboratory, University Medical Center Utrecht
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

-
Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

-
PreventionGenetics, part of Exact Sciences
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Elliptocytosis 2 Benign:2
Jan 12, 2018
Illumina Laboratory Services, Illumina
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease. -

Jul 15, 2021
Genome-Nilou Lab
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Hereditary spherocytosis type 3 Benign:2
Jan 12, 2018
Illumina Laboratory Services, Illumina
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease. -

Jul 15, 2021
Genome-Nilou Lab
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Pyropoikilocytosis, hereditary Benign:2
Jan 12, 2018
Illumina Laboratory Services, Illumina
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease. -

Jul 15, 2021
Genome-Nilou Lab
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.52
CADD
Benign
3.8
DANN
Benign
0.92
PhyloP100
-0.31
Mutation Taster
=100/0
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.030
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs435080; hg19: chr1-158655036; COSMIC: COSV108215571; API